Septerna stock
SEPNNASDAQSepterna Inc, HealthcareISIN US81734D1046
49Score 49 out of 100, Weak
Price and trend
89 / 100
Price history
+118% in one yearThe chart shows daily closes over 2 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 27% above it.
Since September 2025 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 53).
The price is 20% below its 52-week high. Largest decline in 2 years: 81% (December 2024 to April 2025).
Chart figures for advanced users
- SMA 50$40.35
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$33.03
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)53
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$19.23
- The lowest closing price of the last twelve months.
- Resistance$52.34
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Septerna Inc belongs to the Biotechnology industry (United States) and, with a market value of $1.99B, is number 129 of 289 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $45.95M (up 4,174.5% year on year) and a loss of $48.88M.
- For fiscal 2026, analysts expect on average revenue of $96.04M (up 109%) and adjusted earnings per share of −$1.35.
Show more
- MEQIRI Score 49 out of 100 (Weak): rank 389 of 702 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $478.6M, financial debt $21.99M.Stability 69
Weaknesses
- Loss-makingLoss of $59M over the last 12 months.Fundamentals 17
- Negative free cash flowFree cash flow −$77.59M over the last 12 months.Fundamentals 17
- Volatile share priceVolatility 69% a year over the last 12 months.Stability 69
Its standout strengths are momentum and technical analysis, while capital allocation and fundamentals hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 48 to 49.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredA fair value is not meaningful here, so the signal follows the valuation grade.
Valuation metrics
The model puts the fair value at more than four times the share price. That says more about the assumptions than about the company, so a fair value is not meaningful here and the valuation relies on the P/E and the other metrics.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the quarter to 30 Sep 2026, revenue fell 12.2% on the same quarter a year earlier. Revenue has grown strongly since 2023, at around 1644% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 100%, operating −176%, net −106%. Last 12 months: net −61%.
Debt & balance sheet
latest quarterDebt is low; no interest coverage is reported.
Earnings
- Next earnings
- 8 Mar 2027in 115 days
- Last reported
- 9 Nov 2026EPS reported −$0.57 (expected −$0.42)below expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- −$1.350.0%
- Revenue
- $96.04M0.0%
- Earnings per share
- −$2.28−0.2%
- Revenue
- $73.62M0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 5 insiders sold, $73.95M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Bhatt ElizabethSale
15 Oct 2026, President and COO
- Shares
- 4,000
- Price
- $37.41
- Value
- $149,644
- Long Daniel D.Sale
1 Sept 2026, SVP, Drug Discovery
- Shares
- 3,333
- Price
- $37.83
- Value
- $126,078
- Third Rock Ventures V, L.P.Sale
12 Aug 2026, Major holder
- Shares
- 147,200
- Price
- $50.27
- Value
- $7.4M
Show 10 more
- Ra Capital Management, L.p.Sale
12 Aug 2026, Board
- Shares
- 1,493,000
- Price
- $42.50
- Value
- $63.45M
- Bhatt ElizabethSale
11 Aug 2026, President and COO
- Shares
- 25,000
- Price
- $44.00
- Value
- $1.1M
- Long Daniel D.Sale
3 Aug 2026, SVP, Drug Discovery
- Shares
- 3,334
- Price
- $34.47
- Value
- $114,920
- Bhatt ElizabethSale
15 Jul 2026, President and COO
- Shares
- 4,000
- Price
- $33.99
- Value
- $135,974
- Long Daniel D.Sale
1 Jul 2026, SVP, Drug Discovery
- Shares
- 3,333
- Price
- $34.36
- Value
- $114,528
- Shaikhly SamiraSale
29 Jun 2026, Chief People Officer
- Shares
- 2,178
- Price
- $35.18
- Value
- $76,622
- Long Daniel D.Sale
22 Jun 2026, SVP, Drug Discovery
- Shares
- 15,000
- Price
- $35.51
- Value
- $532,582
- Shaikhly SamiraSale
12 Jun 2026, Chief People Officer
- Shares
- 6,250
- Price
- $35.08
- Value
- $219,224
- Shaikhly SamiraSale
1 Jun 2026, Chief People Officer
- Shares
- 5,935
- Price
- $28.93
- Value
- $171,682
- Shaikhly SamiraSale
26 May 2026, Chief People Officer
- Shares
- 11,798
- Price
- $30.06
- Value
- $354,656
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Septerna
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 49
- Sector median
- 53
Categories against the sector medianMedian of 702 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Vera TherapeuticsVERA $2.1B35
- Vir BiotechnologyVIR $2.08B52
- Recursion PharmaceuticalsRXRX $2.07B36
- First Tracks BiotherapeuticsTRAX $2.05B48
- Harmony Biosciences HoldingsHRMY $1.98B72
- BioCryst PharmaceuticalsBCRX $1.98B37
- Agios PharmaceuticalsAGIO $1.9B39
- Fortrea HoldingsFTRE $1.9B41
ETFs that hold Septerna
Held by 10 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.14% | 0.35% | €1.25B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.04% | 0.30% | €4.28B |
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.04% | 0.30% | €185.82M |
Show 5 more
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.04% | 0.30% | €2.22B |
| State Street SPDR MSCI World Small Cap UCITS ETF (Acc)ZPRS | 0.01% | 0.45% | €1.54B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.01% | 0.43% | €2.5B |
| UBS MSCI USA Select Factor Mix UCITS ETF USD accUSUE | 0.00% | 0.25% | €178.55M |
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.00% | 0.30% | €964.08M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 23 Oct 2026)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.